Research Information Only — Educational content, not medical advice. Humanin is an investigational peptide, not FDA-approved. Physician review required before use.
PeptideReport.ai
Longevity Hub › Humanin

Compound Profile · Longevity / Cellular Health Hub

Humanin

Mitochondrial-derived peptide (MDP) · cytoprotective & neuroprotective signal

A peptide your own mitochondria write — encoded not in the cell's nucleus but inside mitochondrial DNA itself. Humanin is one of the body's built-in "stay alive under stress" signals, and one of the most credible longevity-associated molecules in human biology. It's also mostly preclinical, and this profile keeps those two facts side by side.

Mitochondrial-Derived PeptideCytoprotectiveNeuroprotectiveLongevity-AssociatedInvestigational
mtDNAWhere it's encoded
↓ with ageCirculating levels
MDPSame family as MOTS-c
PreclinicalMost evidence
The Peptide Evidence Index
See how all 34 peptides rank by the strength of real human evidence — one honest scorecard.
View the Index →

Why This Page Exists

A longevity signal worth understanding — and not overselling

Humanin is genuinely fascinating: a peptide the mitochondria produce to protect cells, whose levels track with aging and, in some studies, with human longevity. That makes it a magnet for hype. The honest version is more interesting than the hype: a real endogenous signal with strong mechanistic and animal support, and human data that is still mostly associative. This page holds both — the promise and the ceiling of what's actually known.

In one sentenceHumanin is a mitochondrial-derived peptide that protects cells from stress and apoptosis, supports metabolic and neuronal resilience, and is associated with longevity — with most direct evidence still at the preclinical stage.

Regulatory Status

Legal & regulatory context

United States — FDA
Investigational · Not Approved

Humanin is a research peptide, not FDA-approved for any indication. It is studied in laboratory and animal models and early human investigation.

Endogenous
Body-Made Signal

Humanin is naturally produced from mitochondrial DNA and circulates in human blood. Its levels are measurable and decline with age.

WADA
Verify Independently

Not a mainstream sport-doping target, but classification can shift — competitive athletes should confirm current status.

Analogs
HNG & Potent Variants

Research often uses more stable, more potent analogs (e.g., the "HNG" variant) than native humanin — relevant when interpreting study doses.

Mechanism of Action

How Humanin works

01

It's written in mitochondrial DNA

Humanin belongs to a class called mitochondrial-derived peptides (MDPs), encoded within the mitochondrial genome rather than the nucleus. This places it at the center of how mitochondria communicate their status to the rest of the cell and body — retrograde signaling from the cell's power plants.

mtDNA (16S rRNA region) → Humanin → cytoprotective & metabolic signaling
02

It blocks apoptosis — the cell-suicide program

A core action is suppressing programmed cell death, in part through interaction with pro-apoptotic proteins such as BAX. In practical terms, humanin helps stressed cells survive insults that would otherwise kill them — the basis of its cytoprotective and neuroprotective reputation.

03

It interacts with the IGF-1 / metabolic axis

Humanin engages IGF-binding-protein and metabolic signaling, linking it to insulin sensitivity, metabolic stress resistance, and the same longevity pathways studied across the MDP family. This is where its metabolic and healthspan interest comes from.

04

The longevity association

Higher circulating humanin has been observed in long-lived individuals and their offspring, and levels fall with age. That makes humanin a candidate biomarker and mediator of healthspan — an association that is real and repeatedly observed, but not the same as proof that supplementing it extends human life.

Primary Use Cases

What Humanin is studied for

  1. Neuroprotection Preclinical
    The most-studied area — protection of neurons against stress and toxicity, with heavy interest in Alzheimer's and neurodegeneration models. Mechanistically strong; not clinically proven in humans.
  2. Metabolic & cardiometabolic resilience Preclinical
    Improved insulin sensitivity and protection of metabolic tissues under stress in animal models.
  3. Longevity / healthspan Associative
    Human association studies linking higher humanin to longevity; animal lifespan/healthspan work. Promising, associative, not causal in humans.
  4. Cellular stress protection (broad) Preclinical
    Cytoprotection across cardiac, retinal, and other tissues in models of oxidative and ischemic stress.
Humanin vs. MOTS-cBoth are mitochondrial-derived peptides. MOTS-c leans metabolic — AMPK activation, energy, insulin sensitivity. Humanin leans protective — keeping cells alive under stress, especially neurons. Complementary siblings, not interchangeable. See MOTS-c.

Evidence Summary

What the research shows — and doesn't

DomainTypeKey finding
NeuroprotectionPreclinicalProtects neurons from apoptosis and toxicity in Alzheimer's and stress models; among the earliest and strongest mechanistic findings.
Longevity associationHuman observationalHigher circulating humanin in long-lived people and their offspring; age-related decline in levels.
Metabolic protectionAnimalImproved insulin sensitivity and tissue protection under metabolic stress.
Cytoprotection (multi-organ)PreclinicalCardiac, retinal, and vascular protection in oxidative/ischemic injury models.

Evidence strength by area

Neuroprotection (mechanism)
Preclinical-strong
Longevity association
Associative
Metabolic resilience
Preclinical
Human clinical outcomes
Very early
Honest evidence noteHumanin's mechanism and animal data are compelling, and its longevity association in humans is real. But controlled human outcome trials are essentially not there yet. Treat it as a scientifically serious, still-investigational compound — not a proven anti-aging therapy.

Protocols

Dosing consensus

Human dosing is not established by clinical trials; the reference ranges below come from research analogs and community practice, and warrant physician oversight given the thin human record.

Subcutaneous — research referenceLow-microgram to low-milligram ranges, protocol-dependent

Potency varies dramatically between native humanin and stabilized analogs (e.g., HNG), so a single "standard dose" is misleading. Any protocol should specify which form it refers to.

Cycling & contextCourse-based, reassessed

Typically used in defined courses rather than open-ended, and most rationally as part of a longevity/cellular-health strategy rather than a standalone fix.

Red Flags & Cautions

Where Humanin needs care

Common Questions

Humanin questions answered

What makes Humanin different from other peptides?
It's encoded inside mitochondrial DNA, not the cell nucleus — making it a "mitochondrial-derived peptide." It's a signal the cell's own power plants send to protect the cell and coordinate metabolism, which is a fundamentally different origin than most therapeutic peptides.
Does it actually extend lifespan?
In humans, the evidence is associative — higher humanin correlates with longevity, and levels drop with age. Animal work supports healthspan roles. But no controlled human trial shows that taking humanin extends human lifespan. It's a serious longevity candidate, not a proven longevity drug.
Humanin or MOTS-c — which should I care about?
They do different jobs. MOTS-c is the metabolic one (energy, AMPK, insulin sensitivity). Humanin is the protective one (keeping cells, especially neurons, alive under stress). In a longevity framework they're complementary, not competing.
Is it safe?
Its endogenous nature is reassuring, but human safety data is limited, and its anti-apoptotic (cell-survival) mechanism means real caution is warranted with any cancer history. Physician oversight is appropriate given how early the human evidence is.

Related Research

Longevity & cellular-health hub

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and longevity medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every profile is an independent synthesis of the primary literature, evidence-graded and corrected in the open. No products are sold on this site.

Full Disclaimer

Humanin is not approved by the U.S. Food and Drug Administration for any indication and is an investigational research peptide with predominantly preclinical evidence. Information on this page is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. Longevity associations are observational and do not establish that supplementation extends human lifespan. Any use should be under the supervision of a qualified physician, with particular caution given the compound's anti-apoptotic mechanism in the context of malignancy. PeptideReport.ai does not manufacture, sell, or endorse any peptide preparation. Content addresses adults 21 and older. Evidence and regulatory classifications continue to evolve.